Corium Inc. is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative healthcare therapies for the central nervous system (CNS). The company focuses on providing clinicians with advanced treatment options that benefit patients, their families, and caregivers. Corium's lead investigational product, Corplex Donepezil, is a transdermal formulation of donepezil, commonly prescribed for Alzheimer's disease, designed to deliver sustained and controlled doses over a week. Additionally, Corium is set to lead the commercialization of KP415, an investigational product for Attention Deficit Hyperactivity Disorder (ADHD) developed by KemPharm, Inc. This product aims to offer a new treatment option for ADHD patients, pending regulatory approval. Corium operates in the biopharmaceutical market, targeting healthcare providers and patients in need of CNS therapies. The company's business model revolves around developing proprietary transdermal technologies and partnering with other pharmaceutical firms to commercialize their products. Revenue is generated through product sales, licensing agreements, and milestone payments from partnerships.

Keywords: transdermal solutions, CNS therapies, Alzheimer's treatment, ADHD medication, biopharmaceutical, commercialization, donepezil, KP415, healthcare innovation, patient care.